Neumeier Poma Investment Counsel LLC Takes Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Key Points

• Neumeier Poma Investment Counsel LLC has acquired a new stake in Prestige Consumer Healthcare Inc., purchasing 101,350 shares valued at approximately $8.7 million.
• Institutional investors and hedge funds dominate ownership of Prestige Consumer Healthcare, holding 99.95% of the company's stock.
• Recent earnings reports indicate that Prestige Consumer Healthcare exceeded analyst expectations with an EPS of $1.32 and revenue of $296.52 million for the quarter.

Neumeier Poma Investment Counsel LLC purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 101,350 shares of the company's stock, valued at approximately $8,713,000. Neumeier Poma Investment Counsel LLC owned 0.20% of Prestige Consumer Healthcare as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. Cerity Partners LLC boosted its holdings in Prestige Consumer Healthcare by 3.7% during the first quarter. Cerity Partners LLC now owns 3,666 shares of the company's stock worth $315,000 after purchasing an additional 132 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Prestige Consumer Healthcare by 0.7% during the fourth quarter. Franklin Resources Inc. now owns 21,735 shares of the company's stock worth $1,697,000 after purchasing an additional 150 shares during the last quarter. KBC Group NV boosted its holdings in Prestige Consumer Healthcare by 7.4% during the first quarter. KBC Group NV now owns 2,199 shares of the company's stock worth $189,000 after purchasing an additional 151 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after purchasing an additional 152 shares during the last quarter. Finally, McIlrath & Eck LLC raised its position in Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after acquiring an additional 154 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $75.09 on Thursday. The company's 50-day moving average is $80.00 and its 200-day moving average is $82.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82. The firm has a market capitalization of $3.71 billion, a PE ratio of 17.50, a PEG ratio of 2.22 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a fifty-two week low of $64.94 and a fifty-two week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The company had revenue of $296.52 million during the quarter, compared to analysts' expectations of $289.36 million. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. Prestige Consumer Healthcare's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.02 EPS. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on PBH. Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and a consensus price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.